ORKA News and Press, Oruka Therapeutics Inc. From 08/11/25

First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025 MENLO PARK, Calif...

Leatt Corp (LEAT) is expected to report for Q2 2025 MDU Resources Group Inc. (Holding Company) (MDU) is expected to report $0.13 for Q2 2025 Video Display Corp. (VIDE) is expected to report for quarter end 2025-05-31 Alarm.com Holdings Inc. (ALRM) is expected to report $0.38 for Q2 20...

IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026 Interim Phase 1 data and further details on EVERLAST-A study design to be shared in an oral presentation at EADV in September MENLO PARK, Calif., July 2...

2025-07-01 16:13:56 ET More on Oruka Therapeutics Historical earnings data for Oruka Therapeutics Financial information for Oruka Therapeutics Read the full article on Seeking Alpha For further details see: Oruka Therapeutics announces COO appointment

MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), toda...

MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today annou...

Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to three times per year in psoriasis, a significant improvement over standard of ca...

Replimune Group Inc. (REPL) is expected to report $-0.75 for Q4 2025 Adcore (ADCOF) is expected to report for Q1 2025 Equillium Inc. (EQ) is expected to report $-0.22 for Q1 2025 Credicorp Ltd. (BAP) is expected to report $5.31 for Q1 2025 Pelangio Exploration Inc (PGXPF) is expec...

2025-05-14 17:31:52 ET More on Oruka Therapeutics Historical earnings data for Oruka Therapeutics Financial information for Oruka Therapeutics Read the full article on Seeking Alpha For further details see: Oruka Therapeutics GAAP EPS of -$0.40 beats by $...

Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout expected in 2H 2026 that will provide ...